Table 1.
Prevention of diabetes in ZDF rats
| Blood glucose, mg/dl
|
Plasma insulin, ng/dl
|
Plasma triglyceride, mg/dl
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Treatment time, weeks
|
Treatment time, weeks
|
Treatment time, weeks
|
|||||||
| 0 | 4 | 12 | 0 | 4 | 12 | 0 | 4 | 12 | |
| Zucker lean | |||||||||
| Control | 137 ± 3 | 131 ± 1 | 143 ± 3 | 0.78 ± 0.13 | 1.08 ± 0.17 | 1.4 ± 0.3 | 74 ± 1 | 110 ± 8 | 134 ± 8 |
| Troglitazone | 132 ± 2 | n.d. | n.d. | n.d. | 80 ± 7 | n.d. | |||
| ZDF | |||||||||
| Control | 146 ± 4 | 447 ± 25 | 675 ± 25 | 5.87 ± 0.62 | 13.32 ± 1.26 | 3.5 ± 0.4 | 80 ± 2 | 1107 ± 66 | 813 ± 85 |
| Troglitazone | 131 ± 2** | 162 ± 3* | 8.86 ± 0.62** | 20.9 ± 1.6** | 120 ± 5** | 362 ± 16** | |||
Male Zucker (fa/fa) rats or lean littermates (n = 6–9 for each group) were 6 weeks old when troglitazone treatment began. Blood glucose, plasma insulin, and triglycerides levels were determined 4 weeks and 12 weeks after troglitazone treatment. Data are means ± SEM. Differences are statistically significant for *P < 0.05, **P < 0.001 compared to troglitazone treated rats. n.d., not determined.